Abstract
The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.
Original language | English (US) |
---|---|
Article number | e23660 |
Journal | OncoImmunology |
Volume | 2 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2013 |
Keywords
- Anti-PD1
- Cancer immunotherapy
- Immune checkpoint blockade
- Nivolumab
- Re-induction
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology